Price history
¥7,518Latest+230.7%
Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
In one line
null
Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.
Companies sharing a theme
News
Key numbersShowing 8 of 20
PER
33.9How many years of earnings it would take to buy the stock. The market average is generally considered to be around 15.PBR
3.31How many times the company's net assets? Around 1x is generally considered a benchmark.ROE
9.8%Earning power. A figure above 10% is generally considered good.Dividend yield
0.0%The annual dividend as a percentage of the share price.Market capitalization
¥15tnShare price × number of shares. The value of the entire company.Equity ratio
50.7%The proportion of assets funded by money that does not have to be repaid.Operating margin
32.5%The percentage of revenue remaining from the company’s core business.Revenue growth (3 years)
12.6%The average annual growth in sales over the past three years.What to watch next
Completion and integration progress of the approximately ¥32.6 billion acquisition of a Danish rolling tobacco brand, including disclosure of the completion timing, costs and synergies
By the end of 2026 (based on media reports)Impact MediumLikelihood Medium
Continued growth in RRP-related revenue, with the trend from ¥55,824 million at the end of June 2025 to ¥78,571 million at the end of June 2026 continuing
Upcoming quarterly and annual resultsImpact MediumLikelihood High
Updates to the policy regarding the operating model for the Russian tobacco business, including separation options, and the extent of loss estimates, particularly the degree to which uncertainty that cannot currently be reasonably estimated is resolved
Undecided; ongoing disclosureImpact HighLikelihood Medium
New policies and recommendations concerning tighter regulation, such as developments toward a principle-based ban on the use of heated tobacco products while dining, and whether they affect sales or demand
Dependent on the timing of policy announcements and implementationImpact HighLikelihood Medium
What to watch next
Who owns itTop holders total 58.8%
Listed holders 58.8%Everyone else 41.2%
Minister of Finance37.55%
The Master Trust Bank of Japan (Trust Account)10.42%
Custody Bank of Japan, Ltd. (Trust Account).3.47%
SMBC Nikko Securities1.43%
THE NOMURA TRUST AND BANKING CO., LTD. (repurchase)1.30%
STATE STREET BANK AND TRUST COMPANY1.27%
JP MORGAN CHASE BANK0.90%
バークレイズ証券/BNYM0.84%
2 other listed holders1.58%
| Holder | Ownership (%) |
|---|---|
| Minister of Finance | 37.55 |
| The Master Trust Bank of Japan (Trust Account) | 10.42 |
| Custody Bank of Japan, Ltd. (Trust Account). | 3.47 |
| SMBC Nikko Securities | 1.43 |
| THE NOMURA TRUST AND BANKING CO., LTD. (repurchase) | 1.30 |
| STATE STREET BANK AND TRUST COMPANY | 1.27 |
| JP MORGAN CHASE BANK | 0.90 |
| バークレイズ証券/BNYM | 0.84 |
| 2 other listed holders | 1.58 |
This company's documents
Filings
Timely disclosures
- 2026-07-30Notice Regarding Dividend from Retained Earnings (Increase in Dividend) and Revision of Dividend Forecast
- 2026-07-30Fiscal 2026 Second-Quarter Financial Results Briefing Materials (CFO Presentation)
- 2026-07-30Flash Report on Consolidated Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending December 2026 [IFRS]
- 2026-06-29Notice Regarding Completion of Payment for the Disposal of Treasury Shares as Restricted Stock Compensation and Performance Share Units
- 2026-06-05Notice Concerning the Disposal of Treasury Shares as Restricted Stock Compensation and Performance Share Units
- 2026-05-08Fiscal 2026 First-Quarter Results Briefing Materials (CFO Presentation)
- 2026-05-08Summary of Financial Results for the First Quarter of the Fiscal Year Ending December 2026 [IFRS] (Consolidated)
- 2026-02-27Notice of Independent Officer Status
19 more
- 2026-02-272026年 第41回定時株主総会招集ご通知に際しての交付書面に記載しない事項
- 2026-02-272026年 第41回定時株主総会招集ご通知
- 2026-02-12FY2025 Financial Results〔IFRS〕(Consolidated)
- 2025-12-01会社分割(簡易吸収分割)による当社医薬事業の塩野義製薬株式会社への承継完了に関するお知らせ
- 2025-10-302025年12月期 第3四半期 決算短信〔IFRS〕(連結)
- 2025-09-01子会社株式の譲渡完了に関するお知らせ
- 2025-07-312025年12月期 第2四半期(中間期)決算短信〔IFRS〕(連結).pdf
- 2025-05-072025年12月期 第1四半期 決算短信〔IFRS〕(連結)
- 2025-05-07連結子会社の異動(子会社株式の譲渡)に関するお知らせ
- 2025-05-07会社分割(簡易吸収分割)による当社医薬事業の塩野義製薬株式会社への承継に関するお知らせ
- 2025-03-10当社グループのカナダ子会社に対する訴訟の和解及び訴訟損失引当金の計上に関するお知らせ
- 2025-02-13FY2024 Financial Results〔IFRS〕(Consolidated)
- 2024-10-312024年12月期 第3四半期決算短信〔IFRS〕(連結)
- 2024-10-08米国「Vector Group Ltd.」株式に対する公開買付けの結果及び子会社の異動に関するお知らせ
- 2024-08-21当社グループによる米国たばこ会社「Vector Group Ltd.」の買収に関する契約締結について
- 2024-08-022024年12月期 第2四半期(中間期)決算短信〔IFRS〕(連結)
- 2024-05-092024年12月期 第1四半期決算短信〔IFRS〕(連結)
- 2023-10-31Third-Quarter Earnings Summary for the Fiscal Year Ended December 2023 [IFRS] (Consolidated)
- 2023-08-23Notice Regarding a Change in a Specified Subsidiary